Wavepaths

Idea

Introduction

Wavepaths provides an approach to wellbeing that reconnects us with our innate capacities to heal through music, technology & psychedelic science. We are founded on a simple insight - our ways of being, our ways of relating to ourselves & others, are shaped by our experiences. We bring together the Masters of Experience: musicians, artists, engineers, psychotherapists & neuroscientists - to develop Experience as Medicine. Led by design & grounded in research, we deliver this through adaptive, personalised, digital music experiences.

Covid 19 has fundamentally changed the way we operate both personally and professionally. It has only increased our need for tools and services that support mental health and wellbeing remotely. Our personalised, generative music system facilitates transformative experiences with music, remote or in-person, for use during psychedelic therapy, psychotherapy & coaching, or for self-guided use at home.

Substantial accomplishments to date

• Sell-out pop-up Space - an adaptive, immersive experience in collaboration with Brian Eno, Jon Hopkins, Greg Haines and L-Acoustics, building a waitlist of +2400.

• 98% reported improvement in well-being, 60% improvements of 8 out of 10 or better. 86% reporting the experience was personally meaningful. 70% of guests requested return visits.

• Conducted 3 research studies, a light art study, acute and longitudinal experience studies. Results confirmed foundations of our approach and emerging insights into mechanisms.

• Developed these insights into our generative music system, producing ever-evolving music designed to meet specific therapeutic goals and adaptive to musical preference, intention and psychological state.

• Clinic beta has facilitated 500 therapy sessions with patients so far, either supporting psychedelic therapy or as a standalone therapeutic experience with music.

• We have over 1800 psychedelic therapists, psychotherapists and clinics on our waitlist.

• Developed a robust research strategy to further build the evidence base for the use of music both for and as psychedelic therapy.

• Confirmed research partnerships with four psychedelic therapy studies at leading academic institutions, with more in the pipeline.

• Support MAPs Europe's clinical trial into MDMA for PTSD with a bespoke music tool.

• Consumer experience is coming in ‘21 with a waiting list of 15,000.

• Featured in Wired, Rolling Stone, GQ, Evening Standard, Sydney Morning Herald.

Monetisation strategy

Care-Providers

Music for psychedelic therapy - our clinical platform delivers the optimum musical environment for a psychedelic therapy session, removing the guesswork and allowing therapists to focus on the patient. According to drug type, administration, dose, patient preferences and therapeutic requirements, music be adapted live to meet evolving patient needs.

Music as psychedelic therapy - our platform offers psychotherapists, coaches and guides the ability to create personalised, therapeutic ‘psychedelic’ experiences with music alone for clients.

Available via tiered subscription for clinics, private practices, therapists, coaches & guides.

Care-Seekers

Our consumer product offers individuals the ability to create therapeutic experiences with music at home. Adaptive to individual preferences, psychological state and therapeutic intention, a supportive musical environment for emotional reconnection and release. Available via a monthly / annual subscription.

Use of proceeds

Focus of our investment of time and resources over the next six months is on launching our therapist platform out of beta. Having deepened our understanding and insight into the particular needs of each of our target customer segments through a comprehensive therapist research program, we are in a position to be able to roll out a commercial grade interface / feature set for psychotherapy and self-guided home use. Meanwhile we will continue to refine our enterprise offering and support for new psychedelic drugs (MDMA/psilocybin) in partnership with clinical trials at leading academic institutions globally. Around 50% of this raise is allocated towards design and development. A lean, remote team means we can maintain modest burn for payroll and operational expenses, 23% and 6% respectively. 21% is allocated to marketing, sales and support to facilitate launches to our go to market customer segments, therapists and guides in Q4 2020, clinics in Q1 2021.